Cargando…

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis

BACKGROUND: Tumor mutation burden (TMB) is an important biomarker to predict response to anti-PD-L1 treatment across cancer types. TruSight Oncology 500 (TSO500) is currently used globally as a routine assay for TMB. METHODS: Between 2019 and 2021, 1744 patients with cancer received TSO500 assay as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Jaeyun, Heo, You Jeong, Park, Sehhoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152061/ https://www.ncbi.nlm.nih.gov/pubmed/37094985 http://dx.doi.org/10.1136/jitc-2022-006454

Ejemplares similares

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
por: Negrao, Marcelo V, et al.
Publicado: (2021)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
por: Acúrcio, Rita C., et al.
Publicado: (2022)

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
por: Labriola, Matthew Kyle, et al.
Publicado: (2020)

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
por: Takamatsu, Shiro, et al.
Publicado: (2022)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022)

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
por: Al-Showbaki, Laith, et al.
Publicado: (2023)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression
por: Huang, Richard S.P., et al.
Publicado: (2021)

Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
por: So, WeiQing Venus, et al.
Publicado: (2023)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
por: Zhang, Xiaozhen, et al.
Publicado: (2022)

Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
por: Camy, Florian, et al.
Publicado: (2020)

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB(2) harmonization project comparing three NGS panels
por: Ramos-Paradas, Javier, et al.
Publicado: (2021)

Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management
por: Marté, Jennifer L, et al.
Publicado: (2020)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
por: Starzer, Angelika M, et al.
Publicado: (2021)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020)

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
por: Baldelli, Elisa, et al.
Publicado: (2021)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors
por: Chen, Di, et al.
Publicado: (2020)

Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
por: Van Damme, Helena, et al.
Publicado: (2021)

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
por: Ieranò, Caterina, et al.
Publicado: (2022)

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
por: Zhang, Libin, et al.
Publicado: (2021)

Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression
por: Huang, Richard S.P., et al.
Publicado: (2021)

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
por: Sui, Qiaoqi, et al.
Publicado: (2021)

CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
por: Yang, Moran, et al.
Publicado: (2021)

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
por: Lopez de Rodas, Miguel, et al.
Publicado: (2022)

Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response
por: Kelly, Andrew D, et al.
Publicado: (2021)

CD71(+) erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors
por: Bozorgmehr, Najmeh, et al.
Publicado: (2023)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2021)

MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas
por: Wang, Qiang-Wei, et al.
Publicado: (2021)

Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial
por: Stenmark Tullberg, Axel, et al.
Publicado: (2023)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
por: Bochem, Jonas, et al.
Publicado: (2021)

Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer
por: Mao, Misha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o3a0g1p183m59fs0dnapoi45li